Proton beam may spare heart and lungs in breast cancer radiation
NCT ID NCT03270072
First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times
Summary
This study looks at 100 women with stage II or III breast cancer to see if proton beam radiation causes less damage to the heart and lungs than standard X-ray radiation. Participants receive either type of radiation as part of a larger trial. Researchers will measure changes in heart function and lung tissue using imaging and scans. The goal is to find out which radiation method is safer for nearby organs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- proton beam radiation
- What this could lead to
- If successful, this could show that proton beam radiation causes less heart and lung damage than conventional radiation for breast cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures side effects, not whether one radiation type cures cancer better. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2017
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients enrolled at Massachusetts General Hospital on the Radiation Therapy Oncology Group (RTOG) Trial 3510 (Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial). (NCT02603341).
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Eligible for and scheduled to receive radiation therapy on Radiation Therapy Oncology Group (RTOG) Trial 3510 (Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial). (NCT02603341) * Ability to understand and the willingness to sign a study-specific written informed consent document Exclusion Criteria: * There are no exclusion criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer stage II are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to wipe out breast cancer before surgery
- Can a chemo pill mop up hidden breast cancer cells?
- Cooler caps may keep hair on during chemo
- Could a pill replace chemo for some breast cancer patients?
- Could a pill replace chemo for older breast cancer patients?
- Tape or laser: which eases Post-Mastectomy arm swelling better?